No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

in StudyGraphics

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

RelatedReports

Quick Take: Hospital volume and outcomes for acute pulmonary embolism

Cardiology

Analysis of clinical outcomes utilizing ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism

April 30, 2025

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

StudyGraphics

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

April 22, 2025

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs

Gastroenterology

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

April 16, 2025

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports